Clinical Trials Directory

Trials / Unknown

UnknownNCT04511559

Methylation Analysis of Circulating Tumor DNA in Gastric Cancer

Methylation Analysis of Circulating Tumor DNA in Early Diagnosis and Prognostic Stratification in Patients With Gastric Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
540 (estimated)
Sponsor
Shanghai Zhongshan Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The primary purpose of this trial is to describe the profile of ctDNA methylation in gastric cancer. The second purpose is to demonstrate the correlation between the plasma ctDNA methylation status and the diagnosis and prognosis of patients with early and intermediate stage gastric cancer.

Detailed description

Gastric cancer represents one of the common malignant tumors in China, with high incidence and mortality rates. Surgery is the conventional treatment option for early and intermediate stage gastric cancer, but the diagnosis in the early stage of gastric cancer remains a challenge to clinical practitioners. Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA with an average size of 166 bp, mixed with cell-free DNA (cfDNA) of other sources in blood circulation. ctDNA is reflecting the most up-to-date status of the tumor genome. Hence, it is considered as a novel biomarker for tumors, which can be qualitative, quantitative, and used for disease monitoring. This study is designed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) as a clinical index in the diagnosis and prognosis of gastric cancer. The primary purpose of this trial is to describe the profile of ctDNA methylation in gastric cancer. The second purpose is to demonstrate the correlation between the plasma ctDNA methylation status and the diagnosis and prognosis of patients with early and intermediate stage gastric cancer.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCirculating Tumor DNA Methylation SequencingWhole blood collection through venipuncture. DNA methylation levels by deep sequencing.
DIAGNOSTIC_TESTtissue DNA Methylation SequencingIsolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.

Timeline

Start date
2020-10-01
Primary completion
2023-09-30
Completion
2025-05-01
First posted
2020-08-13
Last updated
2020-08-13

Source: ClinicalTrials.gov record NCT04511559. Inclusion in this directory is not an endorsement.